Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAPY3: Fecal Microbiota Transfer in ICU Patients
NCT03350178Phase 2Terminated
- Sponsor
- MaaT Pharma
- Start
- Jan 2018
- Primary completion
- Feb 2019
- Modality
- Live Biotherapeutic Products, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of MaaT013, sponsored by MaaT Pharma. Started Jan 2018; status: terminated.
02
Drugs
MaaT013
Beyond the preview
Go deeper on NCT03350178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03350178.